

Market Round-up

V34 – 8th February, 2019

General Market News:

- **The False Medicines Directive** comes into effect this Saturday **9th February**. See the quick guide below for the transition period.
[LINK](#)
- **Novartis** and **Vertex** battle the Netherlands government over pricing
[LINK](#)
- **GSK** and **Merck Group** strike immunotherapy deal worth up to \$4 billion
[LINK](#)
- **GSK** profit beats estimates with strength of **shingles** vaccine sales
[LINK](#)
- **GSK** drops 6 drugs from their pipeline
[LINK](#)
- **BMS** yanked its **Celgene** bid days before deadline—and got a better price
[LINK](#)
- **Novartis** spend on digital and data ‘in the 100s of millions’ collating more than two million patient years of **clinical trial data**.
[LINK](#)

NCPE Drug Updates

- A full HTA is recommended for **Astellas’s Enzalutamide** (Xtandi®)

Biosimilars/Biologics:

- **Pfizer** looks to **oncology** biosimilars to break US market
[LINK](#)

Drug Approvals/Filings:

- **AstraZeneca’s RSV** drug take a big step forward receiving both **EMA PRIME** scheme and **FDA Breakthrough** status
[LINK](#)
- European advisory group backs **MSD’s Keytruda** in first-line lung cancer
[LINK](#)
- **FDA** To review regulatory filings by **MSD** for two **antibacterial agents**
[LINK](#)
- **NICE** recommends **Novartis** CAR-T **Kymriah** for lymphoma
[LINK](#)

- **FDA** has granted Priority Review status to both of **MSD's** two new drug applications
[LINK](#)
- **FDA** has granted approval to **Perrigo's** generic **Zovirax** cream
[LINK](#)
- **Pfizer's** new lung cancer drug **Vizimpro** gets a positive opinion from EMA, recommending marketing approval
[LINK](#)
- **CHMP** recommends EU approval of **Roche's Tecentriq**
[LINK](#)

Brexit:

- No-deal Brexit would push health service into 'damage limitation' mode says Jim Breslin Secretary General at the Department of Health
[LINK](#)
- Brexit: Customs checks to be simplified in no-deal situation
[LINK](#)